Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment

Bone Marrow Transplantation

Volumn 21, Issue 7, 1998, Pages 731-734

  Sonneveld, P ^a   Lameris J S ^a   Cornelissen, J ^a   Ogilvie, A ^a   Lowenberg B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Echography; Stem cell transplantation; tPA; Venoocclusive disease; VOD

Indexed keywords

ALTEPLASE; BUSULFAN; CYCLOPHOSPHAMIDE; FIBRINOLYTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD FLOW; CASE REPORT; COLOR ULTRASOUND FLOWMETRY; CONDITIONING; FIBRINOLYTIC THERAPY; HEPATIC VEIN; HUMAN; LIVER BLOOD FLOW; MALE; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL; PORTAL VEIN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VEIN OCCLUSION;

EID: 2642597079     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701155     Document Type: Article

References (21)

1. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
2. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
3. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 16: 116-122.
4. Jones RJ, Lee KSK, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-785.
5. Ringden O, Labopin M, Tura S et al. A comparison of busulphan vs total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Br J Haematol 1996; 93: 637-645.
6. McDonald GB, Sharma P, Matthews DE et al. The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603-608.
7. Brugieres L, Hartmann O, Benhomou E et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplantation 1988; 3: 53-58.
8. Ayash LJ, Hunt M, Antman K et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699-1706.
9. Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 439-443.
10. Nevill TJ, Barnett MJ, Klingemann H-G et al. Regimen-related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
11. Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator. Bone Marrow Transplant 1990; 5: 439-442.
12. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
13. Laporte JP, Lesage S, Tilleul P et al. Alteplase for hepatic veno-occlusive disease complicating bone marrow transplantation. Lancet 1992; 339: 1057-1059.
14. Rosti G, Bandini G, Belardinelli A et al. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet 1992; 339: 1481-1482.
15. Ringdén O, Wennberg L, Ericzon B-G et al. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet 1992; 340: 546-547.
16. Vu LC, Regueira O, Ode DL, Warrier RP. Recombinant tissue plasminogen activator for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194-198.
17. Morgan M, Dodds A, Atkinson K et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529-534.
18. Meresse V, Hartmann O, Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135-141.
19. Hommeyer SC, Teefey SA, Jacobson AF et al. Veno-occlusive disease of the liver: prospective study of US evaluation. Radiology 1992; 184: 683-686.
20. Brown BP, Abu-Yousef M, Farner R et al. Doppler sonography: a non-invasive method for evaluation of hepatic veno-occlusive disease. AJR 1990; 154: 721-724.
21. Itai Y, Matsui O. Blood flow and liver imaging. Radiology 1997; 202: 306-314.